MyFinsight
Home
Blog
About
US
$99,400K
(-86.92%↓ Y/Y)
Non Us
$26,900K
(-30.67%↓ Y/Y)
US
$109,700K
(-85.56%↓ Y/Y)
Non Us
$16,300K
(-57.99%↓ Y/Y)
US
$59,000K
(-92.23%↓ Y/Y)
Non Us
$6,200K
(-84.02%↓ Y/Y)
US
$6,500K
(-99.14%↓ Y/Y)
Non Us
$300K
(-99.23%↓ Y/Y)
Tyvaso DPI
$326,600K
Remodulin
$126,300K
(-6.24%↓ Y/Y)
Nebulized Tyvaso
$126,000K
(-18.39%↓ Y/Y)
Orenitram
$125,700K
(1.45%↑ Y/Y)
Unituxin
$65,200K
(11.64%↑ Y/Y)
Product And Service
Other
$6,800K
(23.64%↑ Y/Y)
Adcirca
$6,700K
(3.08%↑ Y/Y)
Total revenues
$783,300K
(-1.92%↓ Y/Y)
Interest income
$31,500K
(-38.60%↓ Y/Y)
Other income
(expense), net
$13,300K
(13400.00%↑ Y/Y)
Operating income
$330,800K
(-9.25%↓ Y/Y)
Total other income,
net
$41,900K
(-4.56%↓ Y/Y)
Total operating
expenses
$452,500K
(4.24%↑ Y/Y)
Interest expense
$2,900K
(-60.27%↓ Y/Y)
Income before income
taxes
$372,700K
(-8.74%↓ Y/Y)
Selling, general, and
administrative
$206,700K
(-2.73%↓ Y/Y)
Research and development
$146,300K
(9.18%↑ Y/Y)
Cost of sales
$99,500K
(13.58%↑ Y/Y)
Net income
$333,000K
(7.59%↑ Y/Y)
Income tax expense
$39,700K
(-59.86%↓ Y/Y)
Back
Back
Income Statement
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)
source: myfinsight.com